Nurix Therapeutics's first-quarter performance fell short of expectations, but the stock still rose by 3%

LootboxPhobia · 2026-04-08T13:57:21+00:00

Nurix Therapeutics announces Q1 FY2026 results, with an adjusted loss of -$0.79 per share, below expectations, and revenue of $6.25 million significantly below forecasts. Nonetheless, due to strong cash position, the stock price rose by 3.06%. The company focuses on developing bexobrutideg for chronic lymphocytic leukemia, with R&D expenses increasing.

LootboxPhobia

2026-04-08 13:57:21

Abstract generation in progress

Brisbane, California — Nurix Therapeutics, Inc. (NASDAQ:NRIX) reported first-quarter results for fiscal year 2026 on Wednesday that fell short of analysts’ expectations.

Despite the miss, the company’s stock rose 3.06% in pre-market trading, and investors are focusing on the company’s advancing clinical pipeline and its strong cash position.

This clinical-stage biopharmaceutical company posted an adjusted earnings per share of -$0.79, compared with the consensus analyst estimate of -$0.76, a difference of $0.03. Revenue totaled $6.25 million, below the expected $14.25 million, down 66% year over year; revenue in the prior-year period was $18.50 million. The revenue decline was mainly due to the end of the initial research period for certain drug targets under its collaboration program with Sanofi.

As of February 28, 2026, the company maintained a solid balance sheet, with total cash, cash equivalents, and marketable securities of $540.7 million, down from $592.9 million as of November 30, 2025.

Dr. Arthur T. Sands, President and Chief Executive Officer of Nurix, PhD, MD, said: “Nurix is focusing on implementing a comprehensive registration plan in 2026, with the goal of establishing bexobrutideg as a potential best-in-class option for patients with chronic lymphocytic leukemia.”

Research and development expenses increased from $69.70 million in the prior-year period to $84.10 million, mainly due to higher compensation costs and increased clinical trial expenses as the company accelerates patient recruitment for its bexobrutideg Phase 2 trial. General and administrative expenses rose from $11.70 million in the prior-year period to $14.60 million.

The company is enrolling patients in its DAYBreak CLL-201 pivotal Phase 2 trial, which is intended to support potential accelerated approval for bexobrutideg in relapsed/refractory chronic lymphocytic leukemia. Nurix plans to initiate a global Phase 3 confirmatory trial in mid-2026 and expects to submit IND applications for bexobrutideg for inflammatory and autoimmune indications in 2026.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes